Inosan Biopharma creates unique healthcare treatments to treat neglected health complications in developing regions.

Highlights: AMLO says officials linked to investigation against former Sedena head will be suspended. Claims ‘mafias’ are behind fake flu drugs…

COVID-19 is far from being over but seven months facing the pandemic have make the sector resilient.

Where do authorized third parties stand after the numerous changes and pronunciations regarding COFEPRIS?

Highlights: Ebrard details agreements with AstraZeneca, Pfizer and CanSino. Herrera reports on expenditure. AMLO alleges plot on cancer drugs…

An evolving regulatory environment challenges the medical devices industry. Medisi sees this as an opportunity, rather than a disadvantage.

Clinical trials are important for discovering new treatments, as well as new ways to detect, diagnose and reduce the chance of developing the disease.

Is this increase enough? What other alternatives or initiatives could benefit the sector and help achieve universal coverage?

Product piracy is no longer reserved for luxury product. Many other sectors have been hit, including pharma.